Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.8/5
Jiangsu Recbio Technology (2179 HK)
Watchlist
15
Analysis
Health Care
•
China
Jiangsu Recbio Technology Co., Ltd. develops biotechnology products. The Company produces novel pharmaceuticals, pharmaceutical targets, and other products. Jiangsu Recbio Technology also operates import and export businesses.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Beijing Health Guard Biotechnology
•
26 Mar 2024 00:55
Pre-IPO Beijing Health Guard Biotechnology - The Story of the HPV Vaccine Is Not as Good as Imagined
The real China’s HPV vaccine market could be smaller-than-expected.After being included in National Immunization Program, vaccine business will be...
Xinyao (Criss) Wang
Follow
3.4k Views
Share
bullish
•
Jiangsu Recbio Technology
•
30 May 2023 02:21
•
Broker
Recbio (2179 HK) – Clinical Development of Core Pipeline Products Continues
9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.
CMB International
Follow
278 Views
Share
bullish
•
Jiangsu Recbio Technology
•
20 Dec 2022 18:08
•
Broker
Recbio (2179 HK) – Superior immunogenicity on ReCOV vs. Pfizer’s mRNA vaccine
Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA...
CMB International
Follow
523 Views
Share
bullish
•
Lygend Resources & Technology
•
30 Nov 2022 03:22
Lygend Resources & Technology IPO Trading - Tepid Subscription but Potential Upside Remains
Lygend Resources & Technology (2245 HK) raised US$470m in its Hong Kong IPO. In this note we will talk about the trading dynamics.
Clarence Chu
Follow
410 Views
Share
bearish
•
Chongqing Zhifei Biological Products
•
27 Oct 2022 00:54
Zhifei Biological Products (300122.CH) - More Downside Ahead, with Untenable Logic in HPV Vaccine
Zhifei’s HPV vaccine will face real risk as competing products launch from 2024. The real potential of China HPV vaccine market is much lower than...
Xinyao (Criss) Wang
Follow
196 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.4
x